Skip to main content

Advertisement

Table 4 Association of main baseline characteristics of RA patients with rapid radiographic progression at 2 years (univariate analysis)

From: Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort

  ΔM24–M0 total mSharp >10 P value OR (95 % CI) ΔM24–M0 erosion mSharp > 5 P value OR (95 % CI) ΔM24–M0 joint-space narrowing mSharp >5 P value OR (95 % CI)
  Yes No    Yes No    Yes No   
Age 51.5 ± 10.7 48.2 ± 11.8 0.059 1.03 (0.99–1.05) 51.8 ± 8.9 48.4 ± 11.8 0.108 1.03 (0.99–1.06) 49.4 ± 11.4 48.4 ± 11.7 0.471 1.01 (0.98–1.03)
Female (%) 84.6 81.1 0.543 0.78 (0.35–1.74) 87.5 81.0 0.367 1.64 (0.56–4.83) 83.5 80.9 0.571 1.19 (0.65–2.20)
BMI 25.9 ± 4.9 25.3 ± 4.6 0.245 1.04 (0.98–1.10) 25.1 ± 4.9 25.3 ± 4.6 0.866 0.99 (0.927–1.08) 25.6 ± 4.7 25.2 ± 4.6 0.447 1.02 (0.97–1.07)
RF (%) 69.2 48.2 0.005 2.42 (1.29–4.53) 78.1 41.7 0.005 3.14 (1.37–7.18) 64.9 46.3 0.002 2.15 (1.33–3.47)
ACPA (%) 65.4 41.5 0.001 2.67 (1.45–4.92) 75.0 48.9 0.005 5.0 (2.106–11.872) 59.8 39.6 0.001 2.271 (1.418–3.635)
Total mSharp score 4.0 ± 4.8 3.7 ± 4.4 0.644 1.10 (0.95–1.08) 4.5 ± 5.0 3.7 ± 4.4 0.341 1.04 (0.96–1.12) 3.8 ± 4.8 3.7 ± 4.3 0.837 1.01 (0.95–1.06)
DAS28(ESR)-4v 5.5 ± 1.4 5.3 ± 1.1 0.211 1.2 (0.9–1.5) 5.5 ± 1.5 5.3 ± 1.2 0.331 1.16 (0.86–1.59) 5.3 ± 1.3 5.3 ± 1.1 0.784 1.03 (0.84–1.25)
logCRP level 1.25 ± 0.51 0.98 ± 0.46 0.000 3.3 (1.8–6.3) 1.25 ± 0.49 1.00 ± 0.47 0.004 1.01 (1.00–1.02) 1.16 ± 0.47 0.96 ± 0.46 0.001 2.414(1.445–4.03)
ESR 35 ± 26 28 ± 24 0.009 1.01 (1.00–1.02) 36 ± 29 28 ± 24 0.016 1.01 (1.00–1.02) 32 ± 25 26 ± 21 0.030 1.01 (1.00–1.02)
Steroid use (%) 19.2 13.4 0.264 0.651 (0.305–1.390) 8.0 13.4 0.413 1.66 (0.49–5.65) 83.5 86.6 0.455 0.785 (0.416–1.483)
cDMARD use (%) 89.6 82.2 0.210 1.86 (0.71–4.91) 85.2 83 0.774 1.18 (0.39–3.53) 90.2 80.8 0.041 2.19 (1.03–4.64)
logOPG/TRAIL ratio Q <25 (%) 23.5 25.6   0.894 (0.447–1.787)a 12.9 26.4   0.412 (0.140–1.210)a 26.0 25.1   1.051 (0.619–1.785)a
LogGPG/TRAIL ratio Q25–75 (%) 47.1 50.6 0.685   45.2 50.6 0.041   53.1 49.1 0.614  
logOPG/TRAIL ratio Q >75 (%) 29.4 23.8   1.335 (0.695–2.568)b 41.9 23.0   2.419 (1.136–5.152)b* 20.8 25.8   0.757 (0.432–1.325)b
  1. Data are mean ± SD (median) or percentage. Significant values are in bold
  2. RA rheumatoid arthritis, M month, mSharp score van der Heijde-modified Sharp score, OR odds ratio, 95 % CI, 95 % confidence interval, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, DAS28(ESR)-4v Disease Activity Score in 28 joints, calculated with erythrocyte sedimentation rate (ESR) and four values, CRP C-reactive protein, cDMARD conventional disease-modifying anti-rheumatic drug (used at least at two visits),, OPG osteoprotegerin, TRAIL tumor necrosis factor-related apoptosis-inducing ligand, Q <25 quartile <25th percentile, Q >75 quartile >75th percentile
  3. *p <0.05 p value for comparison of aQ <25th versus Q ≥25th percentile and bQ >75th versus Q ≤75th percentile